Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peretinoin is an orally available small molecule classified as an acyclic retinoid. It acts primarily by binding to and activating nuclear retinoic acid receptor (RAR) and retinoid X receptor (RXR), which leads to the recruitment of coactivator proteins and the promotion of transcription of target genes involved in cell differentiation and apoptosis[1][2][5]. Peretinoin has demonstrated potential antineoplastic and chemopreventive activities. It is being developed mainly for the prevention of recurrence in hepatocellular carcinoma (HCC) after curative therapy[5]. Additional research suggests it may suppress hepatitis B virus replication by modulating sphingosine metabolic pathways and enhance autophagy via increased Atg16L1 expression[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peretinoin.